

1. Details of reporting period

Name of entity:	TrivarX Limited (the Company)
ABN:	58 008 130 336
Reporting period:	30 June 2026
Previous period:	30 June 2025
Presentation Currency	Australian Dollar (\$)

2. Results for announcement to the market

Key information	30 June 2026	30 June 2025	Increase/ (decrease)	Amount change
	\$	\$	%	\$
Revenues from ordinary activities	14,566	1,128,979	(98.71)	1,114,413
Total comprehensive loss attributable to members	(8,915,118)	(972,663)	816.57	7,942,455
Net loss for the year attributable to members	(8,762,643)	(943,231)	829.00	7,819,412

	Amount per Security	Franked Amount per Security
Final Dividend	Nil	Nil
Interim Dividend	Nil	Nil
Previous Corresponding Period	Nil	Nil
Record Date for Determining Entitlements	Not applicable	Not applicable

Commentary on results:

3. Statement of Profit or Loss and other Comprehensive Income

Refer to attached financial statements

4. Statement of Financial Position

Refer to attached financial statements

5. Statement of Cash Flows

Refer to attached financial statements

6. Statement of Changes in Equity

Refer to attached financial statements

7. Dividends

No dividends declared in the current or prior year

8. Details of Dividend Reinvestment Plans

Not applicable

9. Net Tangible Assets Per Share

	30 Jun 2026	30 Jun 2025
Net tangible asset backing per ordinary security (cents)	0.18	0.10

10. Details of entities over which control has been gained or lost during the period

Control gained over entities

Name of entity (or group of entities)	N/A
Date control gained	N/A
Contribution of such entities to the reporting entity's profit/(loss) from ordinary activities during the period (where material)	N/A
Profit/(loss) of the controlled entity (or group of entities) whilst controlled during the whole of the previous corresponding period (where material)	N/A

Loss of control over entities

Name of entity (or group of entities)	N/A
Date control lost	N/A
Contribution of such entities to the reporting entity's profit/(loss) from ordinary activities during the period (where material)	N/A
Profit/(loss) of the controlled entity (or group of entities) whilst controlled during the whole of the previous corresponding period (where material)	N/A

11. Details of Associates and Joint Venture entities

Name of associate or joint venture entity	N/A
Reporting entity's percentage holding in this entity	N/A
Contribution to net profit/(loss) (where material)	N/A
Aggregate share of profits/(losses) of the above entity (where material)	N/A

12. Any other significant information needed by an investor to make an informed assessment of the Company's financial performance and financial position

Refer to attached financial statements
--

13. Foreign entities

Refer to attached financial statements
--

14. Commentary on results for period and explanatory information

Refer to commentary on page 6 of the attached preliminary report.

15. Audit

This Preliminary final report is based on accounts which are in the process of being audited. It is likely that the Auditor will issue an Independent Auditor's Report that will contain an 'Emphasis of Matter' paragraph drawing attention to a material uncertainty that may cast a significant doubt about the Group's ability to continue as a going concern. The attached Preliminary Final Report has been prepared on a going concern basis. Please refer to note 2 Going Concern.

Authorised for release by the Board

A handwritten signature in black ink, appearing to read "D Trimboli".

Mr David Trimboli
Non-Executive Chair

27 August 2026

Statement of Profit or Loss and Other Comprehensive Income.....	2
Statement of Financial Position.....	3
Statement of Changes in Equity.....	4
Statement of Cash Flows.....	5
Notes to the financial statements.....	6

TrivarX Limited
Statement of profit or loss and other comprehensive income
for the year ended 30 June 2026



		Consolidated	
	Note	2026	2025
		\$	\$
Revenue			
Other income		14,566	1,128,979
Expenses			
Employee costs		(1,095,675)	(974,333)
Research and development expenses		(10,344)	(26,393)
Finance costs		(12,489)	(33,627)
Depreciation		(37,310)	(52,467)
Amortisation expenses	4	(6,435,579)	-
Impairment expenses	4	(342,449)	-
Other expenses	3	(843,363)	(985,390)
Loss before income tax expense		(8,762,643)	(943,231)
Income tax expense		-	-
Loss after income tax expense for the year attributable to the Owners of TrivarX Limited		(8,762,643)	(943,231)
Other comprehensive loss			
<i>Items that may be reclassified subsequently to profit or loss</i>			
Foreign currency translation		(152,475)	(29,432)
Other comprehensive loss for the year, net of tax		(152,475)	(29,432)
Total comprehensive loss for the year attributable to the Owners of TrivarX Limited		(8,915,118)	(972,663)
Basic loss per share (cents)		(95.59)	(0.19)
Diluted loss per share (cents)		(95.59)	(0.19)

The above statement of profit or loss and other comprehensive income should be read in conjunction with the accompanying notes

TrivarX Limited
Statement of financial position
as at 30 June 2026



		Consolidated	
	Note	2026	2025
		\$	\$
Assets			
Current assets			
Cash and cash equivalents		2,443,389	1,246,838
Other current assets		47,139	49,929
Total current assets		<u>2,490,528</u>	<u>1,296,767</u>
Non-current assets			
Other assets		4,367	7,756
Right-of-use assets		119,777	164,259
Intangibles	4	13,920,082	12,014,813
Total non-current assets		<u>14,044,226</u>	<u>12,186,828</u>
Total assets		<u>16,534,754</u>	<u>13,483,595</u>
Liabilities			
Current liabilities			
Trade and other payables		316,170	440,006
Lease liabilities		35,925	34,649
Employee benefits		16,722	80,653
Other liabilities		104,608	141,534
Total current liabilities		<u>473,425</u>	<u>696,842</u>
Non-current liabilities			
Lease liabilities		92,211	134,376
Total non-current liabilities		<u>92,211</u>	<u>134,376</u>
Total liabilities		<u>565,636</u>	<u>831,218</u>
Net assets		<u>15,969,118</u>	<u>12,652,377</u>
Equity			
Issued capital	6	113,727,018	109,959,773
Reserves		14,916,867	6,604,728
Accumulated losses		(112,674,767)	(103,912,124)
Total equity		<u>15,969,118</u>	<u>12,652,377</u>

The above statement of financial position should be read in conjunction with the accompanying notes

TrivarX Limited
Statement of changes in equity
for the year ended 30 June 2026



Consolidated	Issued capital \$	Foreign currency translation reserves \$	Share based payments reserves \$	Accumulated losses \$	Total equity \$
Balance at 1 July 2024	106,580,333	(219,617)	6,501,651	(102,968,893)	9,893,474
Loss after income tax for the year	-	-	-	(943,231)	(943,231)
Other comprehensive loss for the year, net of tax	-	(29,432)	-	-	(29,432)
Total comprehensive loss for the year	-	(29,432)	-	(943,231)	(972,663)
<i>Transactions with Owners in their capacity as Owners:</i>					
Net contributions of equity (note 6)	3,680,650	-	-	-	3,680,650
Share-based payments	-	-	285,494	-	285,494
Share issue costs (note 6)	(301,210)	-	66,632	-	(234,578)
Balance at 30 June 2025	<u>109,959,773</u>	<u>(249,049)</u>	<u>6,853,777</u>	<u>(103,912,124)</u>	<u>12,652,377</u>

Consolidated	Issued capital \$	Foreign currency translation reserves \$	Share based payments reserves \$	Accumulated losses \$	Total equity \$
Balance at 1 July 2025	109,959,773	(249,049)	6,853,777	(103,912,124)	12,652,377
Loss after income tax for the year	-	-	-	(8,762,643)	(8,762,643)
Other comprehensive loss for the year, net of tax	-	(152,475)	-	-	(152,475)
Total comprehensive loss for the year	-	(152,475)	-	(8,762,643)	(8,915,118)
<i>Transactions with Owners in their capacity as Owners:</i>					
Net contributions of equity (note 6)	4,394,500	-	-	-	4,394,500
Share-based payments	-	-	8,117,730	-	8,117,730
Share issue costs (note 6)	(627,255)	-	346,884	-	(280,371)
Balance at 30 June 2026	<u>113,727,018</u>	<u>(401,524)</u>	<u>15,318,391</u>	<u>(112,674,767)</u>	<u>15,969,118</u>

The above statement of changes in equity should be read in conjunction with the accompanying notes

TrivarX Limited
Statement of cash flows
for the year ended 30 June 2026



	Consolidated	
	2026	2025
	\$	\$
Cash flows from operating activities		
R&D grant received	-	1,031,073
Payments to suppliers and employees	(1,584,101)	(1,258,156)
Interest received	14,566	8,722
Other (GST refund)	63,759	56,707
Net cash used in operating activities	(1,505,776)	(161,654)
Cash flows from investing activities		
Payments for intangibles	(1,168,736)	(2,091,333)
Net cash used in investing activities	(1,168,736)	(2,091,333)
Cash flows from financing activities		
Proceeds from issue of shares	3,922,129	2,734,321
Proceeds from borrowings	-	500,000
Repayment of borrowings	-	(500,000)
Transaction costs related to loans and borrowings	-	(28,088)
Payment of lease liabilities	(47,964)	(55,108)
Net cash provided by financing activities	3,874,165	2,651,125
Net increase in cash and cash equivalents	1,199,653	398,138
Cash and cash equivalents at the beginning of the financial year	1,246,838	848,096
Effects of exchange rate changes on cash and cash equivalents	(3,102)	604
Cash and cash equivalents at the end of the financial year	2,443,389	1,246,838

The above statement of cash flows should be read in conjunction with the accompanying notes

Note 1. General information

TrivarX Limited ('TrivarX', 'the Company', or 'the Parent') is a for profit company limited by shares incorporated in Australia whose shares are publicly traded on the Australian Securities Exchange.

Note 2. Basis of preparation

The preliminary final report has been prepared in accordance with Australian Accounting Standards and Interpretations issued by the Australian Accounting Standards Board ('AASB') and the *Corporations Act 2001*, as appropriate for for-profit oriented entities. The preliminary final report also complies with International Financial Reporting Standards as issued by the International Accounting Standards Board ('IASB').

This preliminary final report has been prepared in accordance with ASX Listing Rules as they relate to the Appendix 4E and in accordance with the recognition and measurement requirements of the Australian Accounting Standards, other authoritative pronouncements of the Australian Accounting Standards Board, Urgent Issues Group Interpretations and the *Corporations Act 2001*. As such, this preliminary final report does not include all the notes of the type included in an annual financial report and accordingly, should be read in conjunction with the annual report for the year ended 30 June 2025 and any ASX announcements made by the Company during the period.

Going concern

The preliminary final report has been prepared on the going concern basis, which contemplates the continuity of normal business activity and the realisation of assets and settlement of liabilities in the normal course of business. The Group incurred a loss for the year ended 30 June 2026 of \$8,762,643 (2025: \$943,231) and net cash outflows from operations was \$1,505,776 (2025: \$161,654). As at 30 June 2026, cash and cash equivalents was \$2,443,389 (2025: \$1,246,838).

Whilst the Group is expected to be cash-flow negative in the foreseeable future because of research and development activities, the ability of the Group to continue as a going concern is dependent on securing additional funding through equity or debt, or a combination of both to continue to fund its operational and technological development activities. These conditions indicate a material uncertainty that may cast significant doubt about the Group's ability to continue as a going concern and, therefore, that it may be unable to realise its assets and discharge its liabilities in the normal course of business.

The directors believe the Group will continue as a going concern after consideration of the following factors:

- the Group successfully raised \$4,392,000 (before transaction costs) during the financial year ended 30 June 2026 and management has confidence in its ability to raise further capital when required.
- the Group anticipates the receipt, subject to approval, of government grants and tax incentives related to its research and development activities.
- the directors of TrivarX Limited have reason to believe that in addition to the cash flow currently available, the level of expenditure can be managed to meet working capital requirements for at least the next twelve (12) months.

The preliminary final report does not include any adjustments relating to the recoverability and classification of recorded asset amounts or liabilities that might be necessary should the Group not continue as a going concern and meet its debts as and when they become due and payable.

The directors plan to continue the Group's operations on the basis outlined above and believe there will be sufficient funds for the Group to meet its obligations and liabilities for at least twelve (12) months from the date of this report.

Note 3. Other expenses

	Consolidated	
	2026	2025
	\$	\$
Consulting and advisory expenses	349,313	529,790
Insurance	47,631	72,530
Listing fees and share registry charges	69,125	95,549
Legal fees	56,884	56,382
Other administration expenses	320,410	231,139
	843,363	985,390

Note 4. Intangibles

	Consolidated 2026 \$	Consolidated 2025 \$
Development – at cost	4,247,051	4,247,051
Capitalised costs	725,387	679,867
Less: accumulated amortisation	(1,363,077)	-
Less: impairment	(2,241,972)	(2,241,972)
	<u>1,367,389</u>	<u>2,684,946</u>
MEB-001 application development – at cost	8,592,831	8,698,333
Less: accumulated amortization	(4,296,415)	-
	<u>4,296,416</u>	<u>8,698,333</u>
EurAsia development – at cost	1,158,480	446,072
Less: accumulated amortization	(579,240)	-
	<u>579,240</u>	<u>446,072</u>
MLB Proof of Concept development – at cost	342,449	185,462
Less: impairment	(342,449)	-
	<u>-</u>	<u>185,462</u>
Stabl-Im (refer to note 5 for more information)	7,873,884	-
Less: accumulated amortization	(196,847)	-
	<u>7,677,037</u>	<u>-</u>
	<u>13,920,082</u>	<u>12,014,813</u>

Reconciliation of the written down values at the beginning and end of the current and previous reporting period are set out below:

	Capitalised development cost \$	MEB-001 \$	CIP0092- EurAsia \$	MLB Proof of Concept \$	Stabl-Im \$	Total \$
Consolidated	\$	\$	\$	\$	\$	\$
Balance at 1 July 2024	2,695,897	7,433,312	-	-	-	10,129,209
Additions	-	1,258,743	446,072	185,462	-	1,890,277
Foreign exchange variance	(10,951)	6,278	-	-	-	(4,673)
Balance at 30 June 2025	2,684,946	8,698,333	446,072	185,462	-	12,014,813
Additions	-	20,012	733,124	165,600	7,873,884	8,792,620
Foreign exchange variance	45,520	(125,514)	(20,716)	(8,613)	-	(109,323)
Amortisation	(1,363,077)	(4,296,415)	(579,240)	-	(196,847)	(6,435,579)
Impairment (i)	-	-	-	(342,449)	-	(342,449)
Balance at 30 June 2026	1,367,389	4,296,416	579,240	-	7,677,037	13,920,082

(i) Having assessed the relevant impairment indicators of its intangibles as at 30 June 2026, the Company decided to fully impair the costs associated with the MLB Proof of Concept as this application is not expected to derive any future economic benefits.

Note 5. Acquisition of Stabl-Im

On 12 December 2025, the Company acquired all intellectual property associated with the Stabl-Im brain imaging technology from Nucleics Pty Ltd ("Acquisition"). The technology has potential to enable safe imaging and monitoring of brain cancers through standard Magnetic Resonance Imaging (MRI). It represents a potential breakthrough in the safe and non-invasive imaging of brain and other cancers. Stabl-Im uses stable isotope labelling of replicating cells within the brain for earlier detection of brain tumours. Trivarx believes that this is an innovative technology to pursue significant opportunities in the diagnostic imaging and neuro-oncological markets. The Acquisition was approved by shareholders at a General Meeting held on 12 December 2025. Amortisation is calculated using the straight-line method over the expected life of the asset, which is no more than 20 years.

The Acquisition was assessed under AASB 3 using the concentration test and analysis of the elements of a business. The Acquisition was determined to be an asset acquisition.

Consideration

	Fair value \$
Non-refundable option fee	250,000
Performance Shares	5,500,000
Facilitator Options	2,123,884
	<u>7,873,884</u>

Note 6. Issued capital

	2026 Shares	Consolidated 2025 Shares	2026 \$	2025 \$
Fully paid ordinary shares	<u>1,153,693,464</u>	<u>619,826,341</u>	<u>113,727,018</u>	<u>109,959,773</u>

Note 6. Issued capital (continued)

Movements in ordinary share capital

Details	Date	Shares	Issue price	\$
Balance	30 June 2024	409,649,428		106,580,333
Issue of shares	10 July 2024	3,960,000	\$0.0250	99,000
Issue of shares	10 July 2024	14,000,000	\$0.0250	350,000
Placement	10 July 2024	29,029,255	\$0.0250	725,731
Issue of shares	10 July 2024	400,000	\$0.0300	12,000
Issue of shares	4 December 2024	7,831,756	\$0.0220	172,299
Issue of shares	14 January 2025	1,627,653	\$0.0160	26,042
Placement	24 March 2025	56,401,855	\$0.0150	846,028
Placement	24 March 2025	46,417,043	\$0.0150	696,256
Issue of shares	25 March 2025	422,743	\$0.0190	8,032
Issue of shares	25 March 2025	473,314	\$0.0170	8,046
Placement	20 May 2025	47,181,102	\$0.0150	707,717
Issue of shares	10 June 2025	843,213	\$0.0130	10,962
Issue of shares	10 June 2025	1,412,509	\$0.0110	15,537
Issue of shares	10 June 2025	176,470	\$0.0170	3,000
Share issue costs		-		(301,210)
Balance	30 June 2025	619,826,341		109,959,773
Placement (Tranche 1)	27 October 2025	87,274,663	\$0.0080	698,197
Issue of shares	27 October 2025	100,000	\$0.0250	2,500
Issue of shares	2 December 2025	8,767,123	\$0.0219	192,000
Placement (Tranche 2)	19 December 2025	437,725,337	\$0.0080	3,501,803
Share issue costs				(627,255)
Balance	30 June 2026	<u>1,153,693,464</u>		<u>113,727,018</u>

Ordinary shares

Ordinary shares entitle the holder to participate in dividends and the proceeds on the winding up of the Company in proportion to the number of and amounts paid on the shares held. The fully paid ordinary shares have no par value and the Company does not have a limited amount of authorised capital.

On a show of hands every member present at a meeting in person or by proxy shall have one vote and upon a poll each share shall have one vote.

Share buy-back

There is no current on-market share buy-back.

Capital Management

Due to the nature of the Group's activities, the Group does not have ready access to credit facilities, with the primary source of funding being equity and/or debt raisings. Therefore, the focus of the Group's capital risk management is the current working capital position against the requirements of the Group to meet research and development programs and corporate overheads. The Group's strategy is to ensure appropriate liquidity is maintained to meet anticipated operating requirements, with a view to initiating appropriate capital raisings as required. Any surplus funds are invested with major financial institutions.

Accounting policy for issued capital

Ordinary shares are classified as equity.

Incremental costs directly attributable to the issue of new shares or options are shown in equity as a deduction, net of tax, from the proceeds.